The size of the Latin American Cardiovascular Therapeutic Drugs Market is currently worth USD 14.57 billion in 2020 and is projected to reach USD 16.01 billion by 2025, growing at a CAGR of 1.9%. The past few decades have witnessed significant success in the development of highly effective drug therapies for common cardiovascular disease. The widespread use of these therapies along with the rising cardiovascular disease accounts for the increasing market for cardiovascular therapeutics.
Cardiovascular therapeutic drugs are the prescribed drugs and medicines for the diseases that are related to the structure and function of the heart and blood vessels. Cardiovascular diseases are responsible for majority of the deaths globally and continues to cause health problems. These health problems mainly include heart failure, blood clots, coronary artery disease, high cholesterol and others.
The market is driven by a host of factors which includes rise in aging population, rise in per capita spending on healthcare and epidemic of general medical issues like obesity and diabetes. With cardiovascular disorders being the most common cause for morbidity and mortality, the market has a tremendous value and continue to do so in the coming years. However, there are a few restraints the market likes to overcome which includes rising costs for drug development and lowering of target population. And also, despite of high prevalence, drug development pipelines for cardiovascular disorders has been stagnant for a variety of reasons.
Latin America market for cardiovascular therapeutic drugs market is segmented into diseases and drug class. Based on the type of cardiovascular diseases, the market is studied as hypertension, thrombosis, hyperlipidaemia, Arteriosclerosis, Coronary artery disease, Peripheral artery disease, Cardiac arrhythmias, acute coronary syndrome, Myocardial infarction, cardiac failure diseases and other diseases. Asia-Pacific market based on its geographical regions, is segmented into Brazil, Mexico, Argentina and Others.
Some of the leading companies in Cardiovascular Therapeutics Drugs Market includes Johnson & Johnson, Bayer, AstraZeneca, Novartis, Bristol-Myers Squibb, Takeda, Merck, Pfizer Sanofi, and boehringer ingelheim.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Disease
5.1.1 Arteriosclerosis
5.1.2 Cardiac arrhythmias
5.1.3 Myocardial infarction
5.1.4 Acute Coronary Syndrome
5.1.5 Peripheral artery disease
5.1.6 Coronary artery disease
5.1.7 Hypertension
5.1.8 Hyperlipidaemia
5.1.9 Thrombosis
5.1.10 Cardiac failure diseases
5.1.11 Others
5.2 By Drug Class
5.2.1 Monotherapies
5.2.2 Combinatiob Therapies
6. Geographical Analysis
6.1 Introduction
6.2 Brazil
6.3 Mexico
6.4 Argentina
6.5 Rest of Latin America
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 AstraZeneca
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Novartis
9.3 Bristol-Myers Squibb
9.4 Pfizer
9.5 Sanofi
9.6 Merck
9.7 Bayer
9.8 Takeda
9.9 Boehringer Ingelheim
9.10 Johnson & Johnson
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
